宫颈癌组织TUFT1、TRPM7表达及临床意义-东南大学学报医学版

宫颈癌组织TUFT1、TRPM7表达及临床意义

作者：陈曦蓝岚

单位：南京医科大学第四附属医院妇产科, 江苏南京 210000

分类号：R737.33

出版年·卷·期（页码）：2024·43·第五期（777-781）

摘要：

目的: 探讨宫颈癌组织釉丛蛋白1(TUFT1)、瞬时受体电位M7(TRPM7)的表达及临床意义。方法: 收集本院2019年1月至2021年1月间住院手术的110例宫颈癌患者术中切除的宫颈癌组织标本及癌旁组织标本,免疫组化法检测TUFT1、TRPM7的表达;Kaplan-Meier法分析TUFT1、TRPM7表达水平与预后的关系;Spearman相关分析TUFT1、TRPM7表达的相关性;Cox回归分析患者预后的影响因素。结果: 宫颈癌组织较癌旁组织中TUFT1、TRPM7阳性率均增加(P＜0.05);低分化、肿瘤直径≥4 cm、国际妇产科联盟(FIGO)分期Ⅱ+Ⅲ期的患者TUFT1、TRPM7表达阳性率高于中高分化、肿瘤直径＜4 cm、FIGO分期Ⅰ期患者(P＜0.05);宫颈癌组织TUFT1与TRPM7的表达水平呈正相关(r=0.445,P＜0.05);TUFT1阳性表达患者3年生存率(53.66%,44/82)低于TUFT1阴性表达患者(78.57%,22/28)(χ²=4.679,P=0.031);TRPM7阳性表达患者3年生存率(40.98%,25/61)低于TRPM7阴性表达患者(83.67%,41/49)(χ²=19.290,P＜0.001);TUFT1、TRPM7是宫颈癌患者死亡的危险因素(P＜0.05)。结论: TUFT1、TRPM7在宫颈癌组织中高表达,二者与患者3年预后有密切联系,可能成为预后判断的重要生物指标。

Objective: To investigate the expression and clinical significance of Tuftelin-1(TUFT1) and transient receptor potential melastatin 7(TRPM7) in cervical cancer tissue. Methods: Intraoperative cervical cancer tissue specimens and adjacent tissue specimens of 110 patients with cervical cancer who were hospitalized for surgery during January 2019 to January 2021 were collected, and the expressions of TUFT1 and TRPM7 were detected by immunohistochemistry. Kaplan-Meier method was used to analyze the relationship of TUFT1 and TRPM7 expression level with prognosis. The correlation of TUFT1 and TRPM7 expression was analyzed by Spearman correlation analysis. Cox regression was used to analyze the influencing factors of prognosis. Results: The positive rates of TUFT1 and TRPM7 in cervical cancer tissues increased compared to adjacent tissues(P<0.05). The positive expression rates of TUFT1 and TRPM7 of patients with low differentiation, tumor diameter≥4 cm, and International Federation of Obstetrics and Gynecology(FIGO) stage Ⅱ+Ⅲ were higher than those of patients with medium to high differentiation, tumor diameter<4 cm, and FIGO stageⅠ(P<0.05). The expression levels of TUFT1 and TRPM7 were directly correlated(r=0.445, P<0.05). The 3-year survival rate of TUFT1 positive expression patients(53.66%,44/82) was lower than that of TUFT1 negative expression patients(78.57%,22/28)(χ²=4.679, P=0.031). The 3-year survival rate of TRPM7 positive expression patients(40.98%,25/61) was lower than that of TRPM7 negative expression patients(83.67%,41/49)(χ²=19.290, P<0.001). TUFT1 and TRPM7 were risk factors for mortality in cervical cancer patients(P<0.05). Conclusion: TUFT1 and TRPM7 are highly expressed in cervical cancer tissue, and they are closely related to the 3-year prognosis of patients, which may become important biological indicators for prognosis judgment.

参考文献：

[1] COHEN P A,JHINGRAN A,OAKNIN A,et al.Cervical cancer[J].Lancet,2019,393(10167):169-182.
[2] JOHNSON C A,JAMES D,MARZAN A,et al.Cervical cancer:an overview of pathophysiology and management[J].Semin Oncol Nurs,2019,35(2):166-174.
[3] 王芳,崔金全,张海玲,等.TUFT1在卵巢上皮性癌组织中的表达及对卵巢上皮性癌SKOV3细胞生物学功能的影响[J].中华妇产科杂志,2020,55(2):125-129.
[4] DONG R F,ZHUANG Y J,WANG Y,et al.Tumor suppressor miR-192-5p targets TRPM7 and inhibits proliferation and invasion in cervical cancer[J].Kaohsiung J Med Sci,2021,37(8):699-708.
[5] 国家癌症中心,国家肿瘤质控中心宫颈癌质控专家委员会.中国宫颈癌规范诊疗质量控制指标(2022版)[J].中华肿瘤杂志,2022,44(7):615-622.
[6] 章伟玲,姚涓,陈肖静,等.宫颈癌患者肿瘤组织中ANGPTL4和NRIP1蛋白表达水平及与预后的关系[J].中国妇产科临床杂志,2023,24(1):9-11.
[7] BEDELL S L,GOLDSTEIN L S,GOLDSTEIN A R,et al.Cervical cancer screening:past,present,and future[J].Sex Med Rev,2020,8(1):28-37.
[8] CUBIE H A,CAMPBELL C.Cervical cancer screening-the challenges of complete pathways of care in low-income countries:focus on Malawi[J].Womens Health(Lond),2020,16(7):1-10.
[9] VERKERK A J M H,ANDREI D,VERMEER M C S C,et al.Disruption of TUFT1,a Desmosome-associated protein,causes skin fragility,woolly hair,and palmoplantar keratoderma[J].J Invest Dermatol,2024,144(2):284-295.
[10] 史素芳,宋亚娟,尹天露,等.三阴乳腺癌组织中TUFT1和Rab5-GTP的表达水平及临床意义[J].中国实验诊断学,2023,27(3):267-269.
[11] 王坤,张玉盼,杨亚鹏.TUFT1在直肠癌组织中表达及其临床诊断和预后价值[J].中国实验诊断学,2022,26(12):1788-1792.
[12] 曾玉群,李冰,窦常伟.姜黄素通过调控TUFT1/AKT信号通路抑制肝细胞癌增殖、迁移及侵袭研究[J].新中医,2020,52(11):6-9.
[13] CHEN J,WU S,WANG J,et al.Hsa_circ_0074269-mediated upregulation of TUFT1 through miR-485-5p increases cisplatin resistance in cervical cancer[J].Reprod Sci,2022,29(8):2236-2250.
[14] CHUBANOV V,KÖTTGEN M,TOUYZ R M,et al.TRPM channels in health and disease[J].Nat Rev Nephrol,2023,18(1):1-15.
[15] LIU H,DILGER J P,LIN J.A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers[J].Pharmacol Ther,2022,240(1):1-11.
[16] LIU X,GAN L,ZHANG J.miR-543 inhibites cervical cancer growth and metastasis by targeting TRPM7[J].Chem Biol Interact,2019,302(1):83-92.
[17] QI H,LU L,WANG L.Long noncoding RNA ST7-AS1 upregulates TRPM7 expression by sponging microRNA-543 to promote cervical cancer progression[J].Onco Targets Ther,2021,14(1):5059-5060.
[18] NUMATA T,SATO-NUMATA K,OKADA Y.TRPM7 is involved in acid-induced necrotic cell death in a manner sensitive to progesterone in human cervical cancer cells[J].Physiol Rep,2019,7(13):1-12.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录